Lv51
1210 积分 2025-04-15 加入
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
19天前
已完结
Biweekly dosing of efsubaglutide alfa maintains glycaemic and continuous glucose monitoring control in type 2 diabetes: A randomised multicentre trial
1个月前
已完结
Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial
2个月前
已完结
Mapping the effectiveness and risks of GLP-1 receptor agonists
3个月前
已完结
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
3个月前
已关闭
Ecnoglutide, a biased GLP-1 receptor agonist as a potential new player for type 2 diabetes management?
4个月前
已完结
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
5个月前
已完结
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
5个月前
已完结
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
5个月前
已完结
Pharmacokinetic similarity study comparing the biosimilar candidate, LY05008, with its reference product dulaglutide in healthy Chinese male subjects
5个月前
已完结
皖公网安备34019202002308
